for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Biomedical Research and Therapy
   [4 followers]  Follow    
  This is an Open Access Journal Open Access journal
     ISSN (Print) 2198-4093 - ISSN (Online) 2198-4093
     Published by Vietnam National University Homepage  [1 journal]
  • Human umbilical cord blood derived mesenchymal stem cells were
           differentiated into pancreatic endocrine cell by Pdx-1 electrotransfer

    • Authors: Phuoc Thi-My Nguyen, Anh Thai-Quynh Nguyen, Nhung Thi Nguyen, Nguyet Thi-Minh Nguyen, Thu Thi Duong, Nhung Hai Truong, Ngoc Kim Phan
      Abstract: Diabetes mellitus type 1 is an autoimmune disease with high incidence in adolescents and young adults. A seductive approach overcomes normally obstacles treatment is cell-replacement therapy to endogenous insulin production. The pancreatic duodenal homeobox 1 (Pdx1) is essential transcription factor pancreatic development, beta cell differentiation and other metabolic processes. This study aimed to orient umbilical cord blood-derived mesenchymal stem cell (UCB-MSCs) to pancreatic endocrine cells by Pdx1 electrotransfer. The results showed that the low voltage of electrotransfer significantly increased in the efficiency of electrotransfer and survival cells compared with other high voltages. Pdx-1 transfected UCB-MSCs over-expressed pancreatic related genes as Ngn3, Nkx6.1. These results suggested that Pdx1 transfected UCB-MSCs were successfully oriented pancreatic endocrine cells. Different to lentiviral vectors, electrotransfer is a safer method to transfer Pdx-1 to UCB-MSCs and a useful tool in translational research.
      PubDate: 2014-04-26
      Issue No: Vol. 1, No. 2 (2014)
  • Establishment of a standardized mouse model of hepatic fibrosis for
           biomedical research

    • Authors: Nhung Hai Truong, Nam Hai Nguyen, Nguyen Thi-Kim Nguyen, Huy Minh Le, Giang Huong Tran, Nghia Huynh, Thanh Van Nguyen
      Abstract: Liver injury causes the formation of nodules and diffuses fibrosis or scar tissues termed liver fibrosis. Since efficient therapies to prevent fibrosis are not obtainable, it is necessary to build up a potential animal model of liver fibrosis to study. In this research, liver fibrosis micewere generated using Swiss mice and carbon tetrachloride - CCl4. CCl4 at doses of 0.8, 1.0 and 1.2 ml/kg was evaluated on mice to obtain an effective dose for liver fibrosis induction. This study aimed to build up a standardized hepatic fibrosis mouse model induced by carbon tetrachloride for further biomedical research. On Swiss mice, dose of CCL4 was considered and criterias of fibrosis were also evalutated such as serum markers, fibrosis marker-genes and histopathology. Mice were administrated with CCL4 in 8 consecutive weeks, 3 times/week. Body weight, survival rate and serum markers Aspartate aminotransferase/Alanine aminotransferase (AST/ALT), fibrosis markers (fibronectin, procollagen, nt5e, TGF-beta and integrin) and histopathology (Hematoxylin & Eosin staining) were measured to determine the suitable dose of CCL4. Results showed that CCL4 1.0 ml/kg is the efficient dose for liver fibrosis mouse model establishment. In a standardized liver fibrosis model, mice were treated with CCL4 1.0 ml/kg in 11 consecutive weeks, 3 times/week and evaluated serum markers level (AST, ALT, bilirubin, albumin), gene-expression of fibrosis markers using quantitative-RT PCR, histopathology (H&E staining) and connective tissue formation by Massive trichrome staining. The outcomes showed that serum markers and the level of fibrosis gene markers in standardized liver fibrosis mice had significantly increased. It is also recorded that there was a sharply increasing of fibronectin and procollagen expression (1222.40±4.20 and 241.35±1.18, respectively). We also recorded cirrhosis (fibrosis stage 3 – 5/6) in liver tissues of standardized liver fibrosis mice.
      PubDate: 2014-04-25
      Issue No: Vol. 1, No. 2 (2014)
  • Cytokine induced killer cell immunotherapy in cancer treatment: from bench
           to bed side

    • Authors: Arashar Arafar
      Abstract: Cytokine-induced killer (CIK) cells are T effector cells generated by monocytes cultured and stimulated by cytokines. CIK cells were studied for more than 20 years ago. Because they can cause lysis of tumor cells that of both autologous and allogenic origins, they were used in cancer treatment.  This review aimed to summarize advancements of CIK cell research and their recent clinical applications in cancer treatment. In general, CIK cells were widely clinically used for recent 5 years. They gave promising results in breast cancer, lung cancer, renal cancer, and hepatocellular carcinoma treatment. Looking into the future, CIK cell based immunotherapy will become an important tool in cancer treatment. 
      PubDate: 2014-04-15
      Issue No: Vol. 1, No. 2 (2014)
  • Adipose stem cells in clinic

    • Authors: Phuc Van Pham
      Abstract: Adipose derived stem cell (ADSC) is the most popular mesenchymal stem cells (MSCs) used in the clinic in recent years. ADSC transplantation has some advantages compared to others from bone marrow, umbilical cord blood... ADSCs produced important growth factors for wound healing, modulate the immune system, decrease inflammation, and home in on injured tissues. Particularly, ADSC extraction from adipose tissue is a simple procedure with minimum invasion in the patients. Therefore, ADSCs were used in the treatment of many diseases and clinical trials since 2000s. To date, ADSC transplantation was approved in some countries to treat medical complications such graft versus host disease, osteoarthritis... This review is an overview of applications and future challenges of ADSC in clinic.
      PubDate: 2014-03-25
      Issue No: Vol. 1, No. 2 (2014)
  • CD47 target: from theory to reality

    • Authors: John Wu
      Abstract: Irving Weissman at the Stanford University School of Medicine in Palo Alto, California found that leukemia cells produced higher levels of CD47. This high expression help tumor cells to escape from the immune system. To date, the CD47 receptor becomes the interesting target in cancer treatment. Some recent studies from in vitro to pre-clinical trials showed that blocking CD47 by anti-CD47 or morpholino efficiently tumor cells or tumor growth. From these results, some clinical trials were suggested to test the safety and efficacy of anti-CD47 therapy. There is at least a clinical trial using anti-CD47 therapy registered in Some other clinical trials will be performed at Stanford in the mid-2014 as well as in the United Kingdom.
      PubDate: 2014-03-22
      Issue No: Vol. 1, No. 2 (2014)
  • Biological therapy: a new age of cancer treatment

    • Authors: Ngoc Kim Phan
      Abstract: Cancer is an important reason causing death in almost countries. So cancer studies become as interesting research field. Many research groups approached cancer treatment with some different strategies. To date, there are four main strategies used in preclinical and clinical treatment included surgery, chemotherapy, radiation therapy, and biological therapy. In some indications, doctors combined them to make combinatorial therapies. In recent years, biological therapies become a promising therapy, especially in invasive cancer. Biological agents formed the targeting therapies that in principle only cancer cells effected by drugs. Biological therapies as monoclonal antibodies, immune cells based immunotherapies showed that the treatment efficiency in some cancers, in recent years. Biomedical Research and Therapy is developed basing on the progress in research and application of biology, biotechnology in disease treatment that included cancer. So that, in this year, Biomedical Research and Therapy will have a special issue with the theme “Biological therapy for cancer treatment”. We will invite some of the leaders in this field to critically review this issue. We expect that this issue will be of great interest for developing the novel approaches and innovations for cancer treatment.
      PubDate: 2014-03-22
      Issue No: Vol. 1, No. 2 (2014)
  • Diabetic foot ulcer treatment by activated platelet rich plasma: a
           clinical study

    • Authors: Tung Dang-Xuan Tran, Phuong Thi-Bich Le, Phuc Van Pham
      Abstract: Diabetic foot ulcer is a major complication of diabetes mellitus. It occurred in about 15% of all diabetic patients. To date, the outcome of management of diabetic foot ulcer is poor and low sufficient. Some new therapies were suggested to manage and treat this disease. In almost therapies, management of diabetic foot ulcer relates to debridement of the wound, revascularization, off-loading of the ulcer, antibacterial actions, stimulating granulation, epidermization and angiogenesis. This study aimed to evaluate the effects of activated platelet rich plasma (aPRP) on diabetic foot ulcer healing on volunteer patients. There were 6 patients enrolled in this study. All patients have non-healing foot ulcers. aPRP was isolated from peripheral blood and activated with calcium chloride. Patients were injected with aPRP two times with 14-day interval. All patients were monitored during 12 weeks. The results showed that 100% (6/6) ulcers completely closed after about 7 weeks. This result initially suggests that aPRP injection is efficient method to treat the non-healing foot ulcers. Level of evidence: IV.
      PubDate: 2014-03-22
      Issue No: Vol. 1, No. 2 (2014)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014